The Attitudes and Beliefs of Hispanic/Latino Individuals Toward Prescription Opioids and Non-Medical Opioid Use

August 1, 2024 updated by: M.D. Anderson Cancer Center
To better understand how people think and feel about prescribed pain medication, including opioids.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

Primary Objectives:

1. To examine the general attitudes and beliefs of Hispanic/Latino individuals about the use of prescription opioids. The primary outcomes include the responses to questions 13-28 from the Opioid Attitudes and Beliefs survey.

Secondary

  1. To evaluate Hispanic/Latino individuals' reports of personal experiences with the use of opioids. The corresponding outcomes are the responses to questions 1-12 from the Opioid Attitudes and Beliefs survey.
  2. To find out any potential reasons why some Hispanic/Latino individuals may refuse to use clinically indicated opioid prescriptions. These outcomes are the responses to questions 14-15 from the Opioid Attitudes and Beliefs survey.
  3. To explore factors associated with participant's comfort with the use opioid analgesics for their pain. The outcome will be the association between participants' responses to question 2 and their characteristics such as age, gender, race, level of education, extent of acculturation, knowledge of opioids, or previous opioid use.

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • M D Anderson Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

M D Anderson Cancer Center

Description

Inclusion criteria:

  1. Aged 18 years or older.
  2. Ability to understand, read, write, or speak English and/or Spanish.
  3. Ability to give informed consent.
  4. Willingness to participate in the survey.

Exclusion criteria:

1. Refusal to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Opioid Attitudes and Beliefs survey
Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
Other: Opioid Attitudes
Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
Other: Beliefs survey
Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Opioid Attitudes and Beliefs Survey
Time Frame: through completion of study an average of 1 year
The survey questionnaire consists of a total of 33 items in five brief sections and responses are mainly based on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree".
through completion of study an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Collaborators

National Institutional of Health
UT Health Science Center

Investigators

  • Principal Investigator: Joseph Arthur, MD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 23, 2023

Primary Completion (Actual)

July 30, 2024

Study Completion (Actual)

July 30, 2024

Study Registration Dates

First Submitted

September 1, 2022

First Submitted That Met QC Criteria

September 1, 2022

First Posted (Actual)

September 6, 2022

Study Record Updates

Last Update Posted (Actual)

August 2, 2024

Last Update Submitted That Met QC Criteria

August 1, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022-0543
  • NCI-2022-06839 (Other Identifier: NCI-CTRP Clinical Trials Registry)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Opioids

Clinical Trials on Opioid Attitudes

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe